🔗 Share this article

The initial novel therapies for gonorrhoea in many years are being viewed as a "huge turning point" in the fight against increasingly resistant strains of the infection, according to health experts.

A Worldwide Health Concern

Cases of gonorrhoea are increasing globally, with estimates suggesting over 82 million instances per year. Especially elevated rates are seen in the African continent and countries within the World Health Organization's Western Pacific region, which spans from Mongolia and China to New Zealand. Across England, cases have reached a record high, while rates across Europe in 2023 were significantly elevated compared to the rates from 2014.

“The clearance of new treatments for gonorrhoea is an important and timely development in the context of rising global incidence, escalating drug resistance and the highly restricted available drugs at this time.”

Health officials are deeply concerned about the rise in drug-resistant strains. The global health body has listed it as a "critical concern". A tracking program showed that resistance to standard treatments like ceftriaxone and cefixime had risen sharply between 2022 and 2024.

A Pair of Novel Treatment Options Gain Authorization

One new antibiotic, also known as a brand name, was authorized by the US FDA in December for use against gonorrhoea. This infection can lead to serious health problems, including infertility. Experts believe that focused deployment of this new drug will help delay the development of resistance.

Another new antibiotic, created by the drugmaker GSK, gained clearance in close succession. This drug, which is also used to treat urinary tract infections, was demonstrated in studies to be successful in treating drug-resistant strains of the gonorrhoea bacteria.

A Unique Partnership

This new treatment was the result of a innovative non-profit model for medication research. The non-profit organisation Global Antibiotic Research & Development Partnership partnered with the drug firm Innoviva to see it through.

“This approval represents a major breakthrough in the treatment of multidrug-resistant gonorrhoea, which up to this point has been staying ahead of our drug pipeline.”

Clinical Trial Data and Global Access

According to results released by a prominent scientific publication, zoliflodacin eradicated over nine in ten of uncomplicated infections. This places it at an comparable level with the typical regimen, which involves two antibiotics. The trial included nearly 1,000 patients from multiple nations including the United States, Thailand, South Africa, and European nations.

Under the terms of its collaboration, GARDP has the authority to license and sell the drug in many developing nations.

Clinicians treating patients have voiced positive views. The availability of a one-pill regimen such as this is seen as a "critical tool" for managing the epidemic. This is considered vital to alleviate the strain of the illness for patients and to halt the transmission of untreatable gonorrhoea around the world.